8-K: Fennec Pharma Reports Record 2025 Revenue, PEDMARK Growth

Fennec Pharmaceuticals announced record full-year 2025 net PEDMARK product sales of $44.6 million, a 50% year-over-year increase, alongside strategic business advancements and a strengthened financial position.

Summary

• Record annual revenue with full-year net PEDMARK product sales of $44.6 million, representing 50% year-over-year growth.
• Q4 2025 net product sales reached $13.8 million, representing 75% growth over Q4 2024 net product sales.
• Achieved record performance with all-time high patient enrollments and conversion rates in Q4 2025.
• Expanded real-world validation of PEDMARK across new tumor types and patient populations through independent, institution-led research, including new data in adults with Head and Neck Cancer (HNC) and the initiation of two new clinical studies.
• Announced positive topline results from an investigator-initiated clinical study of PEDMARK in Japan, demonstrating hearing protection without compromising cisplatin efficacy.
• Completed oversubscribed $42 million equity offerings and full debt redemption, resulting in $0 debt outstanding as of December 31, 2025.
• Net loss for the full fiscal year 2025 was $10.098 million, compared to $0.436 million in fiscal year 2024.
• Cash and cash equivalents were $36.7 million as of December 31, 2025, an increase of $10.2 million from December 31, 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, driven by exceptional revenue growth and strategic advancements in clinical evidence and financial health. While net loss increased, the underlying operational and market expansion successes are highly positive indicators for future performance.

Positives

• Record annual net PEDMARK product sales of $44.6 million for FY 2025, representing 50% year-over-year growth.
• Q4 2025 net product sales of $13.8 million, representing 75% growth over Q4 2024.
• Achieved record performance with all-time high patient enrollments and conversion rates in Q4 2025.
• Expanded the field team to accelerate growth and increase customer reach.
• Presented new real-world data supporting PEDMARK's potential use in adults with head and neck cancer (HNC), showing safe administration and no disruption to curative-intent cisplatin-based treatment.
• Initiated two new institution-led clinical studies for PEDMARK in adult men with metastatic testicular germ cell tumors (City of Hope) and AYA/adult cancer patients (Tampa General Hospital).
• Announced positive topline results from the STS-J01 clinical trial in Japan, demonstrating PEDMARK's ability to protect hearing without compromising cisplatin efficacy or introducing concerning side effects in pediatric and AYA patients.
• Strengthened financial position by completing oversubscribed $42 million equity offerings and full debt redemption, resulting in $0 debt outstanding as of December 31, 2025.
• Cash and cash equivalents increased by $10.2 million to $36.7 million as of December 31, 2025.

Negatives

• Net loss for the full fiscal year 2025 increased significantly to $10.098 million, compared to a net loss of $0.436 million in fiscal year 2024.
• Loss from operations for FY 2025 was $6.744 million, compared to a gain of $2.568 million in FY 2024.
• Selling and marketing expenses increased to $6.1 million in Q4 2025 from $3.9 million in Q4 2024, and slightly for the full year to $18.6 million from $18.4 million.
• General and administrative (G&A) expenses increased to $8.9 million in Q4 2025 from $4.2 million in Q4 2024, and to $28.8 million for FY 2025 from $23.1 million in FY 2024, primarily due to increased intellectual property-related legal expenses, payroll, and equity-based remuneration.

Risks

• Regulatory and guideline developments may change.
• Scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receive required regulatory clearances or approvals.
• Clinical results may not be replicated in actual patient settings.
• Unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19).
• Protection offered by the company's patents and patent applications may be challenged, invalidated, or circumvented by competitors.
• The available market for the company's products will not be as large as expected.
• The company's products will not be able to penetrate one or more targeted markets.
• Revenues will not be sufficient to fund further development and clinical studies.
• Ability to obtain necessary capital when needed on acceptable terms or at all.
• The company may not meet its future capital requirements in different countries and municipalities.

Future Outlook

The company's strategy is focused on propelling Fennec into its next chapter of growth, driven by increasing PEDMARK adoption, effective field execution, and sustained progress across the organization. They are pursuing registration for PEDMARK in Japan and exploring partnering or licensing opportunities there. Management will also host investor meetings in April 2026 to discuss future plans.

Management Comments

• "Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec into its next chapter of growth."
• "We delivered record net product sales, achieved significant growth within our Fennec HEARS program, and advanced independent clinical evidence generation for PEDMARK — all while driving quarter-over-quarter growth in every quarter in 2025."
• "These results demonstrate increasing PEDMARK adoption across key accounts and patient segments, effective field execution, and sustained progress across the organization."
• "Concurrently, we strengthened our financial position through prudent operating decisions and strategic financial initiatives, including the closing of public and private offerings and the completion of full debt redemption."

Industry Context

StockSavvy.ai notes that Fennec Pharmaceuticals operates in the specialty pharmaceutical sector, addressing a significant unmet medical need: cisplatin-induced ototoxicity, which affects a large percentage of cancer patients, particularly pediatric and AYA populations. PEDMARK's FDA approval and NCCN recommendation position it as a critical preventative agent in a market where no prior preventative therapies existed. The expansion into adult indications and international markets like Japan demonstrates a strategic effort to broaden its impact beyond its initial pediatric orphan drug designation, aligning with broader industry trends of maximizing therapeutic reach and addressing long-term survivorship quality of life.

Comparison to Industry Standards

• PEDMARK is the first and only U.S. FDA approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors, establishing a new standard of care.
• The product has proven efficacy and safety data from two Phase 3 clinical studies (COG Protocol ACCL0431 and SIOPEL 6), which represents a high bar for clinical validation.
• PEDMARK is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network (NCCN) with a 2A endorsement, indicating strong clinical consensus for its use in this broader patient group.
• The positive topline results from the STS-J01 clinical trial in Japan further validate PEDMARK's efficacy and safety in a new geographic and patient cohort, demonstrating its potential to meet global regulatory and clinical standards.
• The company's strategic expansion into adult indications, such as head and neck cancer, through real-world data and investigator-initiated studies, positions PEDMARK to address a wider patient population compared to its initial pediatric focus, potentially expanding its market significantly beyond its orphan drug status.

Stakeholder Impact

• Shareholders: Positive impact due to record revenue growth, strengthened financial position (debt-free, increased cash), and expanded market potential for PEDMARK through new clinical data and international opportunities.
• Patients: Highly positive impact as PEDMARK's adoption accelerates, new data supports its use in broader populations (adult HNC, AYA), and positive results from Japan trial confirm its efficacy in preventing cisplatin-induced hearing loss, improving quality of life for cancer survivors.
• Employees: Positive impact due to the strategic decision to expand the customer-facing team, indicating growth and potential for new roles.
• Creditors: Positive impact as the company completed full debt redemption, resulting in $0 debt outstanding.
• Customers (Healthcare Providers): Positive impact as growing confidence in PEDMARK's clinical value and expanded evidence base reinforces its potential to reshape standard of care.

Next Steps

• Pursuing registration for PEDMARK in Japan.
• Exploring partnering or licensing opportunities for PEDMARK in Japan.
• Management team to host one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 15-16, 2026.
• Additional investigator-initiated studies supporting the use of PEDMARK in additional tumor types and patient populations are under review.

Key Dates

Recommendation

The company demonstrated exceptional year-over-year revenue growth for PEDMARK, indicating strong market adoption and effective commercial execution. The significant strengthening of the balance sheet through a $42 million equity raise and full debt redemption provides a solid financial foundation. Furthermore, the expansion of clinical evidence into new adult indications and positive international trial results in Japan significantly broaden the product's long-term market potential. While the net loss increased, it appears to be a strategic investment in growth and market expansion, which is justified by the strong top-line performance and strategic achievements. These factors collectively present a compelling investment opportunity.

Keywords

Fennec Pharmaceuticals, PEDMARK, PEDMARQSI, cisplatin-induced ototoxicity, hearing loss prevention, pediatric cancer, AYA cancer, specialty pharmaceutical, financial results, Q4 2025, FY 2025, biopharma, oncology, sodium thiosulfate